Neuroprotective effects of argatroban and C5a receptor antagonist (PMX53) following intracerebral haemorrhage

Clinical and Experimental Immunology

Volumn 175, Issue 2, 2014, Pages 285-295

  Li, G ^a   Fan, R M ^a   Chen, J L ^a   Wang, C M ^a   Zeng, Y C ^a   Han, C ^a   Jiao, S ^a   Xia, X P ^a   Chen, W ^a   Yao, S T ^a  

^a ZUNYI MEDICAL UNIVERSITY   (China)

Author keywords

Argatroban; C5aR; Complement; Intracerebral haemorrhage; Microglia

Indexed keywords

ARGATROBAN; BETA TUBULIN; COMPLEMENT COMPONENT C5A RECEPTOR; DNA NUCLEOTIDYLEXOTRANSFERASE; MESSENGER RNA; NEUROPROTECTIVE AGENT; PMX 53; THROMBIN; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; APOPTOSIS; ARTICLE; BLOOD AUTOTRANSFUSION; BRAIN CORTEX; BRAIN EDEMA; BRAIN HEMORRHAGE; BRAIN WATER; CONTROLLED STUDY; CORPUS STRIATUM; DRUG POTENTIATION; ENCEPHALITIS; HEMATOMA; INFLAMMATION; IPSILATERAL CORTEX; MALE; MICROGLIA; MONOTHERAPY; MOUSE; NERVE CELL NECROSIS; NEUROPROTECTION; NICK END LABELING; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; SCORING SYSTEM; UPREGULATION; WATER CONTENT;

ARGATROBAN; C5AR; COMPLEMENT; INTRACEREBRAL HAEMORRHAGE; MICROGLIA;

ANIMALS; APOPTOSIS; BRAIN EDEMA; CEREBRAL HEMORRHAGE; COMPLEMENT C5A; INFLAMMATION; MALE; MICE; MICE, INBRED C57BL; MICE, KNOCKOUT; NEUROPROTECTIVE AGENTS; PEPTIDES, CYCLIC; PIPECOLIC ACIDS; PLATELET AGGREGATION INHIBITORS; RECEPTOR, ANAPHYLATOXIN C5A; RNA, MESSENGER; STROKE; TUBULIN;

EID: 84891600918     PISSN: 00099104     EISSN: 13652249     Source Type: Journal    
DOI: 10.1111/cei.12220     Document Type: Article

References (47)

1. Xi G, Keep RF, Hoff JT. Mechanisms of brain injury after intracerebral haemorrhage. Lancet Neurol 2006; 5:53-63.
2. Xue M, Balasubramaniam J, Parsons KA, McIntyre IW, Peeling J, Del Bigio MR. Does thrombin play a role in the pathogenesis of brain damage after periventricular hemorrhage? Brain Pathol 2005; 15:241-249.
3. Matsuoka H, Hamada R. Role of thrombin in CNS damage associated with intracerebral haemorrhage: opportunity for pharmacological intervention? CNS Drugs 2002; 16:509-516.
4. Babu R, Bagley JH, Di C, Friedman AH, Adamson C. Thrombin and hemin as central factors in the mechanisms of intracerebral hemorrhage-induced secondary brain injury and as potential targets for intervention. Neurosurg Focus 2012; 32:E8.
5. Liang DY, Li X, Shi X etal. The complement component C5a receptor mediates pain and inflammation in a postsurgical pain model. Pain 2012; 153:366-372.
6. Clark JD, Qiao Y, Li X, Shi X, Angst MS, Yeomans DC. Blockade of the complement C5a receptor reduces incisional allodynia, edema, and cytokine expression. Anesthesiology 2006; 104:1274-1282.
7. Woodruff TM, Strachan AJ, Dryburgh N etal. Antiarthritic activity of an orally active C5a receptor antagonist against antigen-induced monarticular arthritis in the rat. Arthritis Rheum 2002; 46:2476-2485.
8. Rynkowski MA, Kim GH, Komotar RJ etal. A mouse model of intracerebral hemorrhage using autologous blood infusion. Nat Protoc 2008; 3:122-128.
9. Ohnishi M, Katsuki H, Fujimoto S, Takagi M, Kume T, Akaike A. Involvement of thrombin and mitogen-activated protein kinase pathways in hemorrhagic brain injury. Exp Neurol 2007; 206:43-52.
10. Asanuma K, Wakabayashi H, Hayashi T etal. Thrombin inhibitor, argatroban, prevents tumor cell migration and bone metastasis. Oncology 2004; 67:166-173.
11. Woodruff TM, Pollitt S, Proctor LM etal. Increased potency of a novel complement factor 5a receptor antagonist in a rat model of inflammatory bowel disease. J Pharmacol Exp Ther 2005; 314:811-817.
12. Woodruff TM, Crane JW, Proctor LM etal. Therapeutic activity of C5a receptor antagonists in a rat model of neurodegeneration. FASEB J 2006; 20:1407-1417.
13. Nakamura T, Xi G, Hua Y, Schallert T, Hoff JT, Keep RF. Intracerebral hemorrhage in mice: model characterization and application for genetically modified mice. J Cereb Blood Flow Metab 2004; 24:487-494.
14. Garrett MC, Otten ML, Starke RM etal. Synergistic neuroprotective effects of C3a and C5a receptor blockade following intracerebral hemorrhage. Brain Res 2009; 1298:171-177.
15. Lavisse S, Guillermier M, Herard AS etal. Reactive astrocytes overexpress TSPO and are detected by TSPO positron emission tomography imaging. J Neurosci 2012; 32:10809-10818.
16. Shirakawa H, Sakimoto S, Nakao K etal. Transient receptor potential canonical 3 (TRPC3) mediates thrombin-induced astrocyte activation and upregulates its own expression in cortical astrocytes. J Neurosci 2010; 30:13116-13129.
17. Jacob A, Hack B, Bai T, Brorson JR, Quigg RJ, Alexander JJ. Inhibition of C5a receptor alleviates experimental CNS lupus. J Neuroimmunol 2010; 221:46-52.
18. Fonseca MI, Ager RR, Chu SH etal. Treatment with a C5aR antagonist decreases pathology and enhances behavioral performance in murine models of Alzheimer's disease. J Immunol 2009; 183:1375-1383.
19. Ducruet AF, Zacharia BE, Hickman ZL etal. The complement cascade as a therapeutic target in intracerebral hemorrhage. Exp Neurol 2009; 219:398-403.
20. Yang S, Nakamura T, Hua Y etal. The role of complement C3 in intracerebral hemorrhage-induced brain injury. J Cereb Blood Flow Metab 2006; 26:1490-1495.
21. Block ML, Zecca L, Hong JS. Microglia-mediated neurotoxicity: uncovering the molecular mechanisms. Nat Rev Neurosci 2007; 8:57-69.
22. Ager RR, Fonseca MI, Chu SH etal. Microglial C5aR (CD88) expression correlates with amyloid-beta deposition in murine models of Alzheimer's disease. J Neurochem 2010; 113:389-401.
23. Huber-Lang M, Sarma JV, Zetoune FS etal. Generation of C5a in the absence of C3: a new complement activation pathway. Nat Med 2006; 12:682-687.
24. Huang FP, Xi G, Keep RF, Hua Y, Nemoianu A, Hoff JT. Brain edema after experimental intracerebral hemorrhage: role of hemoglobin degradation products. J Neurosurg 2002; 96:287-293.
25. Sansing LH, Kaznatcheeva EA, Perkins CJ, Komaroff E, Gutman FB, Newman GC. Edema after intracerebral hemorrhage: correlations with coagulation parameters and treatment. J Neurosurg 2003; 98:985-992.
26. Costa C, Zhao L, Shen Y etal. Role of complement component C5 in cerebral ischemia/reperfusion injury. Brain Res 2006; 1100:142-151.
27. Kim GH, Mocco J, Hahn DK etal. Protective effect of C5a receptor inhibition after murine reperfused stroke. Neurosurgery 2008; 63:122-125; discussion 5-6.
28. Frank MM, Fries LF. The role of complement in inflammation and phagocytosis. Immunol Today 1991; 12:322-326.
29. Wetsel RA. Structure, function and cellular expression of complement anaphylatoxin receptors. Curr Opin Immunol 1995; 7:48-53.
30. Tokodai K, Goto M, Inagaki A etal. C5a-inhibitory peptide combined with gabexate mesilate prevents the instant blood-mediated inflammatory reaction in a rat model of islet transplantation. Transplant Proc 2010; 42:2102-2103.
31. Sun L, Guo RF, Gao H, Sarma JV, Zetoune FS, Ward PA. Attenuation of IgG immune complex-induced acute lung injury by silencing C5aR in lung epithelial cells. FASEB J 2009; 23:3808-3818.
32. Krisinger MJ, Goebeler V, Lu Z etal. Thrombin generates previously unidentified C5 products that support the terminal complement activation pathway. Blood 2012; 120:1717-1725.
33. Nishimura T, Myles T, Piliponsky AM, Kao PN, Berry GJ, Leung LL. Thrombin-activatable procarboxypeptidase B regulates activated complement C5a in vivo. Blood 2007; 109:1992-1997.
34. Griffin RS, Costigan M, Brenner GJ etal. Complement induction in spinal cord microglia results in anaphylatoxin C5a-mediated pain hypersensitivity. J Neurosci 2007; 27:8699-8708.
35. Fleming SD, Phillips LM, Lambris JD, Tsokos GC. Complement component C5a mediates hemorrhage-induced intestinal damage. J Surg Res 2008; 150:196-203.
36. Nagatsuna T, Nomura S, Suehiro E, Fujisawa H, Koizumi H, Suzuki M. Systemic administration of argatroban reduces secondary brain damage in a rat model of intracerebral hemorrhage: histopathological assessment. Cerebrovasc Dis 2005; 19:192-200.
37. Fujimoto S, Katsuki H, Ohnishi M, Takagi M, Kume T, Akaike A. Thrombin induces striatal neurotoxicity depending on mitogen-activated protein kinase pathways in vivo. Neuroscience 2007; 144:694-701.
38. Barreto AD, Alexandrov AV, Lyden P etal. The argatroban and tissue-type plasminogen activator stroke study: final results of a pilot safety study. Stroke 2012; 43:770-775.
39. Xi G, Wagner KR, Keep RF etal. Role of blood clot formation on early edema development after experimental intracerebral hemorrhage. Stroke 1998; 29:2580-2586.
40. Belayev L, Saul I, Curbelo K etal. Experimental intracerebral hemorrhage in the mouse: histological, behavioral, and hemodynamic characterization of a double-injection model. Stroke 2003; 34:2221-2227.
41. Sugg RM, Pary JK, Uchino K etal. tPA stroke study: study design and results in the first treated cohort. Arch Neurol 2006; 63:1057-1062.
42. Fujimoto S, Katsuki H, Kume T, Akaike A. Thrombin-induced delayed injury involves multiple and distinct signaling pathways in the cerebral cortex and the striatum in organotypic slice cultures. Neurobiol Dis 2006; 22:130-142.
43. Liu DZ, Cheng XY, Ander BP etal. Src kinase inhibition decreases thrombin-induced injury and cell cycle re-entry in striatal neurons. Neurobiol Dis 2008; 30:201-211.
44. Rao HV, Thirumangalakudi L, Desmond P, Grammas P. Cyclin D1, cdk4, and Bim are involved in thrombin-induced apoptosis in cultured cortical neurons. J Neurochem 2007; 101:498-505.
45. Kitaoka T, Hua Y, Xi G, Hoff JT, Keep RF. Delayed argatroban treatment reduces edema in a rat model of intracerebral hemorrhage. Stroke 2002; 33:3012-3018.
46. Wu CH, Yang RL, Huang SY etal. Analysis of thrombin-antithrombin complex contents in plasma and hematoma fluid of hypertensive intracerebral hemorrhage patients after clot removal. Eur J Neurol 2011; 18:1060-1066.
47. Lauer A, Cianchetti FA, Van Cott EM etal. Anticoagulation with the oral direct thrombin inhibitor dabigatran does not enlarge hematoma volume in experimental intracerebral hemorrhage. Circulation 2011; 124:1654-1662.